DEF: Natera 2026 Proxy Statement: Governance and Equity Plan

Natera, Inc. has released its 2026 proxy statement detailing director elections, executive compensation, and a proposed amendment to its 2015 Equity Incentive Plan.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 11, 2026, in a virtual-only format.
• Stockholders will vote on the election of four directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation.
• The company is seeking approval to amend the 2015 Equity Incentive Plan to increase the authorized share reserve by 3,200,000 shares.
• Total 2025 revenue reached $2,306.1 million, representing approximately 36% growth over 2024.
• The company processed approximately 3.5 million tests in 2025, a 15% increase over the prior year.
• Natera achieved positive full-year cash flow of approximately $107.6 million in 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive filing, reflecting strong operational growth, improved margins, and a disciplined approach to equity compensation relative to industry peers.

Positives

• Strong financial performance with $2,306.1 million in total revenue, reflecting 36% year-over-year growth.
• Significant improvement in gross margin to 64.7% in 2025, up from 60.31% in 2024.
• Achieved positive full-year cash flow of approximately $107.6 million.
• Oncology test volume grew by approximately 52% year-over-year to 800,800 tests.
• Successful acquisition and integration of Foresight Diagnostics to expand MRD platform capabilities.
• High level of stockholder support for executive compensation, with 95.8% approval in the 2025 advisory vote.

Negatives

• The company continues to rely heavily on equity-based compensation, which dilutes existing shareholders.
• The proposed increase of 3,200,000 shares to the equity incentive plan adds to the potential dilutive impact on stockholders.
• The company reported a net loss of $208.16 million for the 2025 fiscal year.

Risks

• Operating in a highly competitive and rapidly changing diagnostic and biotechnology environment.
• Potential for future dilution of shareholder value due to ongoing equity-based compensation programs.
• Reliance on the ability to attract and retain highly skilled talent in competitive labor markets like Austin and the San Francisco Bay Area.
• Risks associated with reimbursement coverage, product costs, and evolving regulatory landscapes.
• Uncertainty regarding the successful integration of acquired businesses and technologies.

Future Outlook

The company aims to continue its growth strategy by expanding its product portfolio, increasing market share in oncology, women's health, and organ health, and maintaining its focus on clinical evidence generation. Management expects continued headcount growth in 2026 to support business scaling.

Management Comments

• The board believes the share increase in the Equity Plan is necessary to attract and retain highly qualified individuals essential to long-term growth.
• Management emphasizes that 94% of the CEO's total compensation is variable and at-risk, aligning interests with stockholders.
• The company remains committed to making personalized genetic testing a standard of care.

Industry Context

StockSavvy.ai notes that Natera's aggressive use of equity-based compensation is consistent with high-growth biotechnology firms competing for specialized talent in major tech hubs. The focus on oncology and MRD testing aligns with broader industry trends toward personalized medicine and precision diagnostics.

Comparison to Industry Standards

• Natera's total potential equity dilution of 14.78% is below the median of 16.01% for peer companies with market caps between $10 billion and $35 billion.
• The company's share request of 2.26% of common shares outstanding is positioned at the 14th percentile compared to industry peers.
• The company's burn rate of 2.56% in 2025 is consistent with the median of its peer group.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed in the filing.

Related Party Transactions

• Ongoing collaboration and commercialization agreement with MyOme, Inc., involving equity investments and warrants.
• Employment of Daniel Rabinowitz, brother of Executive Chairman Matthew Rabinowitz, as Chief Legal Officer.

Stakeholder Impact

• Shareholders are asked to approve an increase in the equity pool, which may result in dilution.
• Employees benefit from continued equity-based compensation programs.
• The company continues to emphasize sustainability initiatives, including electronic delivery of proxy materials to reduce environmental impact.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 11, 2026.
• Conduct advisory vote on executive compensation frequency.
• Implement the amendment to the 2015 Equity Incentive Plan if approved by stockholders.

Key Dates

Recommendation

The filing reflects strong operational growth and financial discipline, but the company remains in a high-growth, loss-making phase with significant reliance on equity-based compensation, warranting a hold position for conservative investors.

Keywords

Natera, genetic testing, oncology, molecular diagnostics, proxy statement, equity incentive plan, corporate governance, executive compensation